Cargando…

Prognosis and treatment differences between initial and second primary chondrosarcoma

Prognosis and treatment differences between initial and second primary chondrosarcoma (pCS) remain unknown. In the present study, patients with chondrosarcoma diagnosed between January 2004 and December 2015 were identified using the Surveillance Epidemiology and End Results database. Kaplan-Meier c...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Weipu, Kong, Minghao, Yu, Haiyang, Wang, Dongyan, Huang, Xin, Yao, Xudong, Fan, Jie, Geng, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539928/
https://www.ncbi.nlm.nih.gov/pubmed/31289490
http://dx.doi.org/10.3892/ol.2019.10329
_version_ 1783422505242853376
author Mao, Weipu
Kong, Minghao
Yu, Haiyang
Wang, Dongyan
Huang, Xin
Yao, Xudong
Fan, Jie
Geng, Jiang
author_facet Mao, Weipu
Kong, Minghao
Yu, Haiyang
Wang, Dongyan
Huang, Xin
Yao, Xudong
Fan, Jie
Geng, Jiang
author_sort Mao, Weipu
collection PubMed
description Prognosis and treatment differences between initial and second primary chondrosarcoma (pCS) remain unknown. In the present study, patients with chondrosarcoma diagnosed between January 2004 and December 2015 were identified using the Surveillance Epidemiology and End Results database. Kaplan-Meier curves and log-rank tests were used to assess overall survival (OS) and cancer-specific survival. Univariable and multivariable Cox regression analyses were used to determine factors associated with all-cause mortality and cancer-specific mortality. In total, 1,655 eligible patients were included in the cohort of the present study, of which, 1,455 (87.9%) had initial pCS and 200 (12.1%) had second pCS. Patients with second pCS were more frequently diagnosed in the age range of 61–80 years compared with patients with initial pCS (52.5 vs. 43.1%; P<0.001). The OS rate of patients with initial pCS was significantly higher than that of patients with second pCS (78.3 vs. 63.0%; P<0.001). Multivariable logistic regression analyses suggested that second pCS predicted higher all-cause mortality (hazard ratio, 1.72; 95% confidence interval, 1.31–2.26, P<0.001) compared with that in patients with initial pCS. Furthermore, there were no differences observed in the treatment benefits between the patients with initial and second pCS. In conclusion, second pCS was more frequently diagnosed in older patients compared with initial pCS. In addition, the prognosis of patients with second pCS was worse than that of patients with initial pCS, and the treatment is essentially the same for initial and second pCS.
format Online
Article
Text
id pubmed-6539928
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-65399282019-07-09 Prognosis and treatment differences between initial and second primary chondrosarcoma Mao, Weipu Kong, Minghao Yu, Haiyang Wang, Dongyan Huang, Xin Yao, Xudong Fan, Jie Geng, Jiang Oncol Lett Articles Prognosis and treatment differences between initial and second primary chondrosarcoma (pCS) remain unknown. In the present study, patients with chondrosarcoma diagnosed between January 2004 and December 2015 were identified using the Surveillance Epidemiology and End Results database. Kaplan-Meier curves and log-rank tests were used to assess overall survival (OS) and cancer-specific survival. Univariable and multivariable Cox regression analyses were used to determine factors associated with all-cause mortality and cancer-specific mortality. In total, 1,655 eligible patients were included in the cohort of the present study, of which, 1,455 (87.9%) had initial pCS and 200 (12.1%) had second pCS. Patients with second pCS were more frequently diagnosed in the age range of 61–80 years compared with patients with initial pCS (52.5 vs. 43.1%; P<0.001). The OS rate of patients with initial pCS was significantly higher than that of patients with second pCS (78.3 vs. 63.0%; P<0.001). Multivariable logistic regression analyses suggested that second pCS predicted higher all-cause mortality (hazard ratio, 1.72; 95% confidence interval, 1.31–2.26, P<0.001) compared with that in patients with initial pCS. Furthermore, there were no differences observed in the treatment benefits between the patients with initial and second pCS. In conclusion, second pCS was more frequently diagnosed in older patients compared with initial pCS. In addition, the prognosis of patients with second pCS was worse than that of patients with initial pCS, and the treatment is essentially the same for initial and second pCS. D.A. Spandidos 2019-07 2019-05-07 /pmc/articles/PMC6539928/ /pubmed/31289490 http://dx.doi.org/10.3892/ol.2019.10329 Text en Copyright: © Mao et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Mao, Weipu
Kong, Minghao
Yu, Haiyang
Wang, Dongyan
Huang, Xin
Yao, Xudong
Fan, Jie
Geng, Jiang
Prognosis and treatment differences between initial and second primary chondrosarcoma
title Prognosis and treatment differences between initial and second primary chondrosarcoma
title_full Prognosis and treatment differences between initial and second primary chondrosarcoma
title_fullStr Prognosis and treatment differences between initial and second primary chondrosarcoma
title_full_unstemmed Prognosis and treatment differences between initial and second primary chondrosarcoma
title_short Prognosis and treatment differences between initial and second primary chondrosarcoma
title_sort prognosis and treatment differences between initial and second primary chondrosarcoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539928/
https://www.ncbi.nlm.nih.gov/pubmed/31289490
http://dx.doi.org/10.3892/ol.2019.10329
work_keys_str_mv AT maoweipu prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma
AT kongminghao prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma
AT yuhaiyang prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma
AT wangdongyan prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma
AT huangxin prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma
AT yaoxudong prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma
AT fanjie prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma
AT gengjiang prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma